Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma
Ye Yang(Yangtze University), Fenghuang Zhan(Winthrop Rockefeller Foundation), Siegfried Janz(National Research Council Canada), Erik Wendlandt(University of Iowa), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Jumei Shi(Tongji University), Mu Hao(Chinese Academy of Medical Sciences & Peking Union Medical College), Dana N. Levasseur(University of Iowa), Satyabrata Das(University of Minnesota), Hongwei Xu(Minzu University of China), Tao Yi(Second Military Medical University), Zhimin Gu(University of Iowa), Reinaldo Franqui(University of Iowa), Junwei Huang(Beijing Tongren Hospital), Guido Tricot
Cited by 76
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Alternative splicing and cancer: a systematic review
|Signal Transduction and Targeted Therapy|2021|489
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease
|The American Journal of Surgical Pathology|2006|484